Rafferty Asset Management
BTAI icon

Rafferty Asset Management’s BioXcel Therapeutics BTAI Stock Holding History

Rafferty Asset Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-12,352
Closed -$1.32M – 1078
2023
Q2 		$1.32M Buy
12,352
+3,032
+33% +$1.01M 0.01% 748
2023
Q1 		$2.78M Buy
+9,320
New +$3.98M 0.02% 522
2022
Q2 		– Sell
-5,808
Closed -$1.94M – 1144
2022
Q1 		$1.94M Sell
5,808
-357
-6% -$103K 0.01% 607
2021
Q4 		$2M Buy
6,165
+2,427
+65% +$1.04M 0.01% 659
2021
Q3 		$1.81M Sell
3,738
-568
-13% -$250K 0.01% 665
2021
Q2 		$2M Sell
4,306
-127
-3% -$69.2K 0.01% 684
2021
Q1 		$3.06M Buy
4,433
+3,081
+228% +$2.48M 0.02% 480
2020
Q4 		$999K Sell
1,352
-1,408
-51% -$1.1M 0.01% 492
2020
Q3 		$1.91M Buy
2,760
+1,887
+216% +$1.42M 0.02% 428
2020
Q2 		$740K Buy
+873
New +$569K 0.01% 618

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Rafferty Asset Management's BTAI Position: Q3 2023 in Review

Rafferty Asset Management sold out of BioXcel Therapeutics (BTAI) in Q3 2023, closing a stake of 12,352 shares — an estimated $1.32M sold.

Rafferty Asset Management first reported a position in BTAI in Q2 2020 and held it in 10 quarters. The position peaked at $3.06M in Q1 2021. 85 funds tracked by Wall St. Rank hold BTAI as of Q3 2023.

  • Rafferty Asset Management reported no remaining BioXcel Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Rafferty Asset Management sold 12,352 BioXcel Therapeutics shares in Q3 2023, an estimated $1.32M.
  • Rafferty Asset Management first reported a position in BioXcel Therapeutics in Q2 2020 and held it in 10 quarters.
  • Rafferty Asset Management's BioXcel Therapeutics position peaked at $3.06M in Q1 2021.
  • 85 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2023.

Based on Rafferty Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.